

VOLUME 272 • NUMBER 2 • FEBRUARY 1995

JPETAB 272 (2) 477-962 (1995)

ISSN 0022-3565

MARIE SMITH
BROOKDALE HOSPITAL MEDICAL CENTER

MAY 17 1995

The Journal of

PHARMACOLOGY

AND EXPERIMENTAL THERAPEUTICS

*A Publication of The American Society
for Pharmacology and Experimental Therapeutics
Founded by John J. Abel—1909*

Edited for the Society by John A. Harvey

MARIE SMITH SCHWARTZ MEDICAL LIBRARY
BROOKDALE HOSPITAL MEDICAL CENTER



Published by Williams & Wilkins

Broad coverage of pharmacology
in a prestigious journal

THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS


Editor: **John Harvey, PhD**, The Medical College
of Pennsylvania

JPET is respected the world over as one of the leading research journals in the field of pharmacology. Readers find broad coverage of all aspects of the interactions of chemicals with biological systems, including:

- autonomic pharmacology
- analgesia
- behavioral pharmacology
- cardiovascular pharmacology
- cellular pharmacology
- chemotherapy
- clinical pharmacology
- developmental pharmacology
- drug abuse
- drug metabolism & disposition
- gastrointestinal pharmacology
- immunopharmacology
- neuropharmacology
- pulmonary pharmacology
- renal pharmacology
- toxicology

JPET is valuable reading for academic, industrial and clinical pharmacologists as well as toxicologists. The Journal deserves a place in every pharmaceutical and toxicological research laboratory and pharmacology/toxicology department throughout the world.

Monthly



YES! Enter my subscription:

Avoid future rate increases and ensure uninterrupted service—enter your multiyear subscription today!

The Journal of Pharmacology and Experimental Therapeutics
(monthly)

☐ Individual: \$190/yr ☐ Institutions: \$340/yr
(Please add \$65 outside the U.S.; in Canada, also add 7% GST.)
☐ New Subscription ☐ Renewal ☐ 3 yrs ☐ 2 yrs ☐ 1 yr

name _____

address _____

city state zip _____

Williams & Wilkins
A WAVERLY COMPANY

PT 55768

Payment options:

☐ Check enclosed ☐ Bill me
☐ VISA ☐ MasterCard ☐ American Express

card # _____

signature P.O. # _____

MD subscribers must add state sales tax. Subscriptions outside the US and Canada must be prepaid, in US dollars only. In Japan, contact Igaku-Shoin MYW, Ltd. (03) 5689-5400. Rates valid for orders received before October 31, 1995.

Please allow 8 weeks for delivery of your first issue. Surface mail delivery to countries outside the US may take up to 16 weeks. Airmail rates available upon request.

Discounts available to members on all ASPET publications. SAVE 10% when ordering two. SAVE 15% when ordering three. SAVE 20% when ordering all four.

P.O. Box 23291
Baltimore, Maryland 21203-9990

Printed in USA

Broadway House
2-6 Fulham Broadway
London SW6 1AA England
J5068S ZPTT



Announcement **GRANT PROGRAM**

Molecular Devices Corporation offers a limited number of equipment grants to U.S. and International academic institutions performing research in the fields of pharmacology and/or physiology. The intent of this grant program is to provide academic researchers access to the CytosensorR Microphysiometer technology at a substantially reduced cost, thereby enabling researchers the opportunity to make novel discoveries using the Cytosensor System, with the ultimate goal of publication.

Briefly, the Cytosensor System is the latest tool for studying the physiological consequences of receptor activation; it has been shown to be particularly useful for drug discovery and signal transduction research. The System can monitor receptor-mediated responses from living cells in minutes, providing functional dose responses in just a few hours. Receptor activation can be studied even without previous knowledge of the signal transduction pathway.

For a comprehensive information package including guidelines for grant submittal, scientific publications, Application Notes, Technical Bulletins and a Reference Guide please contact:

Molecular Devices Corp.
1311 Orleans Drive
Sunnyvale, CA 94089
Ph: (408) 747-3545
Fx: (408) 747-3602

Deadline for Grant Submission is March 1, 1995

Research Associate in Molecular Biology

Require Masters Degree in Pharmacology or equivalent; Strong background in Pharmacology & Toxicology; expertise in animal handling, animal surgery; cell culture, organ perfusion technique and in state-of-the-art molecular biology techniques such as Southern, northern, and western blot, including PCR, DNA recombination, library screening and the sequencing, mutation, and heterologous expression of cDNA clones; and thorough knowledge of drug metabolizing enzymes, xenobiotic bioactivation, mechanisms of toxicity of pneumotoxic compounds, and molecular biology concepts as applied to the cloning and structure/function relationships of cytochrome P450 genes. Salary \$13.02 per hour, 40 hours per week. Job Order No. 3060018.

Applicants are directed to send resume to:

**Utah Department of Employment
Security, Attn: Pat Redington, 5th Floor
140 East 300 South
Salt Lake City, UT 84111**

Employer is an EEO/AA employer.



Williams & Wilkins Quick Copies. **Tell us today. Read it tomorrow.**

You can get copies of any article published in any Williams & Wilkins journal. It's fast — because we're the primary source, we can fax an article to you within **24 hours** of when we receive your request. It costs less — there are **no copyright fees** and the **cost of faxing is included in the price**. It's affordable — look at the table to the right.

RATES, PER ARTICLE

1-5	pages	\$10
6-10	pages	\$12
11-15	pages	\$15
16-20	pages	\$18
21-25	pages	\$20
26+	pages	\$25

(\$20, Federal Express)

Fax, phone, or mail your citation to:

**Williams & Wilkins
Quick Copies**
428 East Preston Street
Baltimore, MD 21202-3993
Call 1-800-354-9685 (toll free)
Fax 1-410-528-4312



Williams & Wilkins
A WAVERLY COMPANY

DDSAD 55429

ANTI-HUMAN DOPAMINE D₁ RECEPTOR MONOCLONAL ANTIBODY

Antibody used to localize the D₁ dopamine receptor. The antibody has been used successfully in immunoblotting and immunocytochemistry studies using both transfected cells and rat and human brain.

Levey et al. "Localization of D₁ and D₂ dopamine receptors in brain with subtype-specific antibodies." *Proc. Natl. Acad. Sci. USA* **90**, 8861 (1993); Smiley et al. "D₁ dopamine receptor immunoreactivity in human and monkey cerebral cortex: Predominant and extrasynaptic localization in dendritic spines." *Proc. Natl. Acad. Sci. USA* **91**, 5720 (1994).

Available exclusively from RBI — Cat. No. D-187

RECOMBINANT RECEPTORS

Recombinant receptors are reagents for drug discovery activities, including screening of new molecular entities. RBI offers one step access to a growing number of specific G protein-coupled receptor subtypes.

Dopamine	Cat. No.	Adrenergic	Cat. No.
D ₁ (human)*	D-178	β ₁ (human)*	B-143
D _{2S} (human)*	D-179	β ₂ (human)*	B-144
D _{2L} (human)*	D-180		
D ₃ (human)	D-152	Muscarinic	
D ₃ (rat)*	D-181	M ₁ (human)*	M-174
D _{4.2} (human)**	D-177	M ₂ (human)*	M-175
D ₅ (human)*	D-182	M ₃ (human)*	M-176
		M ₄ (human)*	M-177

* Manufactured for RBI by BioSignal Inc. (Montreal, Canada); supplied as ready-to-use frozen cell membranes

**Manufactured for RBI by Panlabs; supplied as non-viable frozen cells

RBI® RESEARCH BIOCHEMICALS INTERNATIONAL

One Strathmore Road, Natick, MA 01760-2447 USA
508-651-8151 • 800-736-3690 • Fax 508-655-1359 • 800-736-2480

Distributors

Australia, Arncliffe • 2-567-5258
Czech Republic, Olomouc • 68-551-7217
Denmark, Roedovre • 44-948822
France, Illkirch • 88-67-14-14

Germany, Köln • 221-497-2034
Israel, Jerusalem • 2-794951
Italy, Milano • 02-5088220
Japan, Tokyo • 03-5684-1622
Korea, Seoul • 2-945-2431

Norway, Oslo • 22-220411
Switzerland, Zurich • 01-312-2124
Taiwan, Taipei • 2-918-1206
United Kingdom, St. Albans • 0727-841414

COPYRIGHT © 1995 BY THE AMERICAN SOCIETY FOR PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

INFORMATION FOR SUBSCRIBERS

THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (ISSN 0022-3565) is an official publication of The American Society for Pharmacology and Experimental Therapeutics and is published by Williams & Wilkins, 428 E. Preston St., Baltimore, MD 21202-3993. Second class postage paid at Baltimore, MD and at additional mailing offices. POSTMASTER: Send address changes to THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 428 E. Preston St., Baltimore, MD 21202-3993.

Frequency: *Monthly:* Four volumes a year beginning in January, April, July, and October.

Correspondence concerning business matters should be addressed to: Customer Service, Subscriptions, Williams & Wilkins, 428 E. Preston Street, Baltimore, MD 21202-3993. Telephone 1-(800) 638-6423 from anywhere in the U.S. and Canada. From other countries, call (410) 528-8555. Fax: (410) 528-8596.

Correspondence regarding editorial matters should be addressed to the Editor: John A. Harvey, Ph.D., Chief, Division of Behavioral Neurobiology, Department of Pharmacology, The Medical College of PA at EPPI, 3200 Henry Avenue—Suite 129, Philadelphia, PA 19129. Telephone: (215) 842-4061 Fax: (215) 843-0690.

For information on Society membership, contact: The American Society for Pharmacology and Experimental Therapeutics, 9650 Rockville Pike, Bethesda, MD 20814. Telephone (301) 530-7060 Fax: (301) 530-7061.

Instructions to Authors appears in the first issue of each volume (January, April, July, October).

Annual Subscription Rates: U.S.: *Personal* \$190.00; *Institutional* \$340.00; *Single copy* \$30.00. **Outside the U.S., except for Japan:** *Personal* \$255.00; *Institutional* \$405.00; *Single copy* \$35.00.

Institutional (multiple reader) rate applies to libraries, schools, hospitals, clinics, group practices, and federal, commercial and private institutions and organizations.

For Japanese rates, please contact: Igaku-Shoin MYW Ltd., 3-23-14 Hongo, Bunkyo-Ku, Tokyo 113, JAPAN. Telephone: (03) 5689-5400 or 5401. Fax: (03) 5689-5402.

PRICES ARE SUBJECT TO CHANGE.

The GST number for Canadian subscribers is 123394371. Country of origin USA.

New subscriptions received before May 1st of each year will begin with the first issue of the year. Subscriptions received between May 1st and October 31st will start with the mid-year issue (July). Subscriptions received after October 31st will start with the first issue of the following year. Subscriptions may start with any current volume's issue upon request.

Renewals should be done promptly to avoid a break in

journal delivery. The Publisher cannot guarantee to supply back issues on late renewals.

Change of address: The publisher must be notified 60 days in advance. Journals undeliverable because of incorrect address will be destroyed. Duplicate copies may be obtained, if available, from the Publisher at the regular price of a single issue. Send address changes to THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 428 East Preston Street, Baltimore, MD 21202-3993. **If a member,** please contact the Society with your change.

Reprints of individual articles are available only from the authors.

Reprints in large quantities, for commercial or academic use, may be purchased from the Publisher. For information and prices call (410) 528-4292.

Microfilm and Microfiche: Prices are available upon request. Microfilm editions may be ordered from Williams & Wilkins.

The Journal subscription list is available for rental on a controlled basis from Williams & Wilkins. All promotional literature must be approved in advance.

Disclaimer: The statements and opinions contained in the articles of THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS are solely those of the individual authors and contributors and not of the American Society for Pharmacology and Experimental Therapeutics or Williams & Wilkins. The appearance of advertisements in the Journal is not a warranty, endorsement or approval of the products or safety. The American Society for Pharmacology and Experimental Therapeutics and the Publisher disclaim responsibility for any injury to persons or property resulting from any ideas or products referred to in the articles or advertisements.

Volume indices appear in the March, June, September, and December issues.

Indexing/Abstracting Services: The Journal is currently included by the following services in print and/or electronic format: *Index Medicus*, *Current Contents (Life Sciences, Science Citation Index, Research Alert [personalized search service]*, *ISI/BioMed [on-line database]*, *Excerpta Medica*, and *Biosciences Information Service*, and *Reference Update/Research Information Systems*.

Copyright Information: THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS is copyrighted by the American Society for Pharmacology and Experimental Therapeutics. No portion(s) of the work(s) may be reproduced without written consent from Williams & Wilkins. Permission to reproduce copies of articles for non-commercial use may be obtained from the Copyright Clearance Center, 222 Rosewood Drive, Danvers, MA 01923, (508) 750-8400, with a fee of \$3.00 per copy.

Copyright © 1995 by the American Society of Pharmacology and Experimental Therapeutics.

AUTHOR INDEX

- Adachi, H., 825
 Adrien, J., 920
 Aguilar, H., 930
 Albrightson, C. R., 689
 Alling, D. W., 604
 Alvarez, I., 832
 Andersson, R. G. G., 786
 Apparsundaram, S., 519
 Atchison, W. D., 645
 Awazu, S., 739
 Azorlosa, J. L., 560
 Badger, A. M., 689
 Banks, S. M., 604
 Barg, J., 699
 Beauchamp, H. T., 612
 Bédard, P. J., 854
 Bell, R. L., 724
 Bemis, K. G., 799
 Berkhout, T. A., 689
 Bigelow, G. E., 628
 Blanchet, P. J., 854
 Bloom, F. E., 815
 Bonkovsky, H. L., 766
 Botla, R., 930
 Boulanger, C. M., 885
 Bouska, J. B., 724
 Bridal, T. R., 714
 Bronk, S. F., 930
 Brooks, D. W., 724
 Brune, K. A., 799
 Bugelski, P. J., 689
 Butelman, E. R., 845
 Butler, A. M., 639
 Cable, E. E., 766
 Calon, F., 854
 Campos, H. A., 732
 Carpené, C., 681
 Carter, D. B., 597
 Carter, G. W., 724
 Chang, R. S. L., 612
 Chastanet, M., 920
 Chiba, S., 744, 838
 Chikkala, D. N., 581
 Childers, S. R., 901
 Collon, P., 681
 Colombo, M., 832
 Cordi, A., 681
 Cuello, A. C., 527
 Danner, R. L., 604
 Dantzler, W. H., 663
 Davies, H. M. L., 901
 de Lorenzi, F. G., 714
 Desforges, B., 498
 Desta, B., 885
 De Vry, J., 920
 Diana, M., 781
 Dillon, G. H., 597
 Di Paolo, T., 854
 Domínguez, J., 732
 Donohue, S., 766
 Drew, G. M., 750
 Dubé, G. P., 799
 Dumont, Y., 673
 Dykstra, L. A., 477
 Eikenburg, D. C., 519
 Elin, R. J., 604
 Ernsberger, P., 581
 Evans, K. K., 663
 Faiman, M. D., 775
 Farfel, G. M., 860, 868
 Farré, A. J., 832
 Fecho, K., 477
 Finkel, M. S., 945
 Fournier, A., 673
 Fox, M., 619
 Fride, E., 699
 Fujita, T., 546
 Fukui, H., 939
 Funae, Y., 939
 Furukawa, Y., 744, 838
 Garaulet, J. V., 658
 Garofalo, L., 527
 Gessa, G., 781
 Gibson, R. E., 612
 Glaser, T., 920
 Glavin, G. B., 832
 Goldberg, S. R., 791
 Gores, G. J., 930
 Grattagliano, I., 484
 Greenwald, M. K., 560
 Griffiths, R. R., 570
 Grundström, N., 786
 Guenther, T. M., 588
 Hamilton, B. J., 597
 Hamon, M., 920
 Harris, R. R., 724
 Hattler, B. G., 945
 Hayashi, M., 739
 Heldman, E., 699
 Hilditch, A., 750
 Hiroi, T., 939
 Ho, A., 652
 Hoffman, W. D., 604
 Hosseini, J. M., 604
 Hoyano, Y., 744
 Hudson, A., 681
 Hunt, A. A. E., 750
 Iga, T., 505
 Ihara, Y., 546
 Im, W. B., 597
 Imaoka, S., 939
 Inoue, T., 546
 Jackson, B., 689
 Jakubowski, J. A., 799
 Johansson-Rydberg, I. G. M., 786
 Jolas, T., 920
 Judd, D. B., 750
 Kagitani, Y., 911
 Kasama, M., 744, 838
 Kawamura, T., 911
 Kawase, Y., 808
 Kerns, W. D., 689
 Kirchengast, M., 885
 Koev, C. A., 604
 Koob, G. F., 815
 Kotaki, H., 505
 Kreek, M. J., 652
 Kurtz, W. L., 799
 Lafontan, M., 681
 Lambrecht, R. W., 766
 Lanni, C., 724
 Laorden, M. L., 658
 Laporte, A. M., 920
 Lauterburg, B. H., 484
 Levine, D. M., 604
 Levy, R., 699
 Liebson, I. A., 628
 Linden, J., 511
 Little, H. J., 876
 Luo, G., 588
 Luthin, D. R., 511
 Lysle, D. T., 477
 Madan, A., 775
 Maisonneuve, I. M., 652
 Malo, P. E., 724
 Martel, J. C., 854
 Maslonek, K. A., 477
 Mayer, O. H., 945
 Mechoulam, R., 699
 Middlemiss, D., 750
 Milanés, M. V., 658
 Min, K.-R., 808
 Moerschbaecher, J. M., 552
 Mue, S., 808
 Mullikin-Kilpatrick, D., 489
 Mumford, G. K., 570
 Muntoni, A., 781
 Murray, M., 639
 Nagai, H., 911
 Nakano, H., 744
 Nakashima, M., 885
 Narita, Y., 911
 Natanson, C., 604
 Nieves, A. L., 758
 Nocerini, M. R., 953
 Nutt, D., 681
 Oddis, C. V., 945
 Oguchi, T., 744, 838
 Ohishi, N., 939
 Ohnishi, A., 546
 Ohtani, M., 505
 Ohuchi, K., 808
 Organ, A. J., 689
 Orita, Y., 546
 Orzi, F., 892
 Otis, E. R., 724
 Pakarinen, E. D., 552
 Panchal, B. C., 619
 Parker, T. S., 604
 Pepe, J. A., 766
 Perrault, G., 708
 Pettigrew, K., 892
 Piercey, M. F., 854
 Piletz, J. E., 581
 Pistis, M., 781
 Polley, J., 750
 Porrino, L. J., 901
 Potchoiba, M. J., 953
 Prada, J., 791
 Pregoner, J. F., 597
 Preston, K. L., 628
 Quezada, Z. M. N., 604
 Quirion, R., 673
 Raber, J., 815
 Remaury, A., 681
 Robertson, M. J., 750
 Ross, B. C., 750
 Rouveix, B., 498
 Rubin, A. L., 604
 Rush, C. R., 570
 Russo, S. M., 766
 Saeki, T., 825
 Saito, I., 825
 Sanger, D. J., 708
 Sawada, Y., 505
 Sawaki, S., 838
 Saya, D., 699
 Schindler, C. W., 791
 Schranz, C., 484
 Schreiber, R., 920
 Seiden, L. S., 860, 868
 Shinyama, H., 911
 Siegl, P. K. S., 612
 Silber, B. M., 953
 Simmons, R. L., 945
 Sinet, M., 498
 Smith, C. B., 892
 Sokoloff, L., 892
 Souda, S., 825
 Spada, C. S., 758
 Spinelli, W., 714
 Spitsbergen, J. M., 645
 Spivey, J. R., 930
 Stewart, A. O., 724
 Stitzer, M. L., 560
 St-Pierre, S., 673
 Strain, E. C., 628
 Sun, Y., 892
 Takagi, N., 546

Takase, Y., 825
Tanabe, J.-I., 808
Tanaka, T., 546
Tella, S. R., 791
Tensfeldt, T. G., 953
Tomita, M., 739
Toyoki, T., 546

Travers, A., 750
Treistman, S. N., 489
Trippodo, N. C., 619
Tuckett, R. P., 758
Uchida, T., 911
Vanhoutte, P. M., 885
Veyries, M.-L., 498

Vogel, Z., 699
Walters, R. R., 854
Watanabe, M., 808, 911
Watson, W. P., 876
Wieland, P., 484
Williams, L. S., 758
Winger, G., 845

Woods, J. H., 552, 845
Woodward, D. F., 758
Wright, S. H., 663
Yabusaki, Y., 939
Yamamura, Y., 546
Yoshitake, S., 825
Zernig, G., 845

Notice to Contributors (Revised July 1, 1994)

Scope of Submitted Manuscripts

The Journal invites for review original papers dealing with interactions of chemicals with biological systems. Any aspect of pharmacology and therapeutics is included, but descriptive case reports without dose response or mechanism studies are not accepted. Manuscripts dealing primarily with new methods will be reviewed only if data are presented showing new or more reliable pharmacological information has been obtained by use of the methods.

Submission of Manuscripts

Submit four copies of manuscript to *Dr. John A. Harvey, Editor in Chief, Journal of Pharmacology and Experimental Therapeutics, Department of Pharmacology, Suite 129, The Medical College of Pennsylvania at EPPI, 3200 Henry Avenue, Philadelphia, PA 19129*, accompanied by a check or purchase order for **\$40.00 manuscript handling fee** (in U.S. funds drawn on a U.S. bank payable to ASPET). If submission of the manuscript handling fee entails personal financial hardship to the author, the fee will be waived. In that event the authors should submit a request for waiver of the fee at the time the manuscript is submitted. Only one copy of rejected manuscripts will be returned. Extra copies of figures will not be returned unless specifically requested at the time the manuscript is submitted.

Manuscripts should be typewritten and double spaced in the English language using one side only of approximately 21.6 by 28 cm paper. One original drawing or photograph of each line figure and four (4) clear copies and/or 4 original drawings or photographs of each halftone figure are required. Pages should not be stapled together.

Authors submitting a manuscript do so with the understanding that if it is accepted for publication, copyright in the article, including the right to reproduce the article in all forms and media, shall be assigned exclusively to the Society for Pharmacology and Experimental Therapeutics. Reasonable requests by authors for permission to reproduce their contributions to the Journal will not be refused. It will be necessary for all authors to sign an assignment of copyright form which will be mailed from the Editorial Office on acceptance of the manuscript. The only exceptions will be manuscripts on work performed by employees of the U.S. Federal Government.

Cover Letter

Each manuscript must be accompanied by a written statement signed by one author: "The undersigned author affirms that the manuscript (title of article) and the data it contains are original, are not under consideration by another journal, and have not been published previously. The studies reported in this manuscript have been carried out in accordance with the Declaration of Helsinki and/or with the Guide for the Care and Use of Laboratory Animals as adopted and promulgated by the National Institute of Health". Authors should also indicate in the cover letter the field of pharmacology to which the research applies.

Organization of the Manuscript

In most cases manuscripts should contain the following sections in the order listed; each section should begin on a new page and all pages should be numbered consecutively.

1. Title page. This should contain the complete title of the manuscript, the names of all authors, and the laboratory of origin. Support for the research should be indicated as a numbered footnote to the title and included with other footnotes on a separate page following the reference section.

2. Running title page. a) A running title: should be included at the top of this page and should contain no more than 35 spaces, including punctuation. It should convey the sense of the full title. Commonly used abbreviations (such as "ATP," "ACh," etc.) may be used in the running title. b) Corresponding author: this page should also contain the name, address, telephone and fax number of the person to whom all correspondence should be sent. c) A list of abbreviations used in the paper should also appear on this page. Additionally, each abbreviation should be defined the first time it is used in the text.

3. Abstract. The abstract should present in a concise form the purpose, the general methods, the findings, and the conclusions of the manuscript. Abstracts should be limited to 200

words; abstracts of more than 250 words will not be accepted.

4. Introduction. This section should not be labeled, but should begin on a new page. It should contain a clear statement of the aims of the reported work or of the hypotheses which the work was designed to test. A brief account of the background of the reported work may also be given in this section.

5. Methods. This section should contain explicit, concise descriptions of all new methods or procedures employed. Modifications of previously published methods should be described. Commonly used methods require only a citation of the original source. When methods are described, the description should be such as to enable the reader to judge their accuracy, reproducibility and reliability and to repeat the experiment. Very extended descriptions of methods may be submitted for deposit with the American Society for Information Science National Auxiliary Publications Service (NAPS) c/o Microfiche Publications, P.O. Box 3513, Grand Central Station, New York, NY 10017. A text reference or footnote stating that the full description is available from NAPS permits interested readers to obtain the information and does not occupy an inordinate amount of Journal space. There is a nominal charge to authors for this procedure; those who request the complete information from NAPS pay a small fee.

6. Results. This section ordinarily contains the experimental data to be presented, but not extended discussions of their significance. Results should usually be presented in graphic or tabular form, rather than discursively. Graphic presentation of data is often preferred but there should not be duplication in text, tables and figures. Sufficient data must be given to allow readers to judge the variability and reliability of the results. Statistical tests used and the data analyzed should be explained so that the findings can be interpreted and evaluated.

7. Discussion. This section should present conclusions to be drawn from the results. Speculative discussion is not discouraged, but the speculation should be based on the data presented and identified as such. The discussion should be as concise as possible, within the limits of the ideas which the authors wish to propose and adequate discussion of related work by others.

8. Acknowledgments. This section should begin on a separate page, have a separate heading, and be placed at the end of the text of the manuscript. Gifts and assistance can be acknowledged here but, financial support should appear in a footnote to the title.

9. References. In text citations give the author's name and the year of publication (e.g., McCarthy, 1952; Ruth and Gehrig, 1929). With more than two authors, the text citation should contain the name of the first author, followed by "et al.," and the date (e.g., Kennedy et al., 1960). In the list of references, entries should be arranged alphabetically by author and not numbered. All authors' names should be given. If reference is made to more than one publication by the same authors in the same year, suffixes (a, b, c, etc.) should be added to the year in the text citation and in the list of references.

The list of references should contain, in sequence, the following information: authors' names and initials, title of the cited article, title of the journal in which it appeared, volume number of the journal, inclusive pagination and year of publication. Abbreviations for journals should conform to the Biosis List of Serials (BioSciences Information Services of Biological Abstracts, Philadelphia, PA 19103). Citations of personal communications, unpublished observations, and papers submitted for publication should be given in parentheses at the appropriate place in the text, not in the list of references. A paper may not be cited as "in press" unless it has been accepted for publication. In such cases the name of the journal must be given.

Examples of references to books, chapters and journal articles follow:

Bruce, M. S.: The anxiogenic effects of caffeine. *Postgrad. Med. J.* 66: 18-24, 1990.
Griffiths, R. R., Bigelow, G. E. and Liebson, I. A.: Human Coffee drinking: Reinforcing and physical dependence producing effects of caffeine. *J. Pharmacol. Exp. Ther.* 239: 416-425, 1986.
Tallarida, R. J. and Murray, R. B.: *Manual of Pharmacologic*

Calculations with Computer Programs. Springer-Verlag, New York, 1987.

Young, A. M. and Sannerud, C. A.: Tolerance to drug discriminative stimuli. In *Psychoactive Drugs: Tolerance and Sensitization*, ed. by A. J. Goudie and M. W. Emmett-Oglesby, pp. 221-270, Humana Press, Clifton, NJ, 1989.

No more than four references should be cited in support of any given point. The authors are responsible for accuracy of such citations and are urged to take the utmost care in proofreading citations and the reference list.

10. Footnotes. All footnotes to the title, authors' names or text should be indicated by arabic numeral superscripts, not by letters or other symbols. The footnotes should be typed in sequence on a separate page, not a text page. Footnotes to tables are discussed under Tables, below.

11. Tables. Each table should be on a separate page. Tables should be numbered consecutively with arabic numerals, and should be designed to fit the column or page size of the Journal. A brief descriptive title should be given at the top of each table. The table number should be given in capital letters, the title in boldface upper and lower case letters (e.g., TABLE 3. **Uptake of labeled drug by rat liver slices**). The footnotes to the tables should be referenced by italicized lower case superscript letters (a, b, c, etc.) and should appear beneath the table involved, not on a separate page of the manuscript. Extensive tabular material not absolutely essential to the manuscript will be accepted for deposit with the ASIS/NAPS (see "Methods," above). In such instances a footnote in the published paper will refer the interested readers to NAPS from which copies may be obtained. Note *Statistics* below for expressions of probability.

12. Legends for figures. These should be numbered consecutively in arabic numerals and should appear on a separate page of the manuscript. Legends should explain the figures in sufficient detail so that frequent referral to the text is unnecessary, but efforts should be made to avoid unnecessary length. Abbreviations in the legends should conform to those in the text (see "Abbreviations," below).

13. Figures. Illustrations should be submitted as unmounted glossy prints, or laser jet quality figures, preferably reduced to single column size (approximately 3½ inches in width) to permit reproduction without further reduction. Otherwise, prints should be no larger than 8 by 10 inches and clear enough to permit reproduction without retouching after reduction. The author's name and address and the number of the figure should be placed on the back of each print. A typed label is usually most satisfactory. Ball type pen should not be used. Note *Statistics* below for expression of probability. Uniform symbolism should be used for all illustrations in a manuscript. Symbols, numbers, and letters in the illustrations must be at least 1.5mm in height after reduction to single column size. The title of each figure should appear in the legend rather than on the figure itself. Photomicrographs and electron micrographs should be labeled with a magnification calibration in micro or Angstrom units. A statement of the magnification should appear in the figure legend.

14. Index Terms. A list of index terms useful in constructing the annual index should be included as the last page of the manuscript.

Statistics

Wherever possible statistical probability (P) in tables, figures, and figure legends should be expressed as * P < .05, ** P < .01 and *** P < .001. For second comparisons the symbols † may be used similarly. Authors are urged to avoid unnecessary complexity and to be consistent within the manuscript. In the event of multiple comparisons within a table, footnotes, a, b, c, etc. should be used.

Abbreviations

Magnitudes of variables reported should be expressed in numerals. Most abbreviations are used without punctuation, with no distinction between singular and plural forms (e.g., 1 mg, 25 mg; 1 sec, 25 sec). The usual prefixes are to be used for multiples or submultiples of the basic units (e.g., kg, g, mg, µg, ng, pg). The following abbreviations, or their properly prefixed multiples or submultiples, may be used without definition in the text, tables and figures:

Units of mass

gram	g
mole	mol
equivalent	Eq
microatom	µat

Units of concentration

molar (moles/liter)	M
normal (Eq/liter)	N
percent	%

Units of length or volume

meter	m
micron	µ
Angstrom	Å
liter (spell out in text)	l

Kinetics

dissociation constant

K_d

Dissociation constant of

enzyme substrate complex
enzyme inhibitor complex
Michaelis constant
maximum initial velocity

K_e

K_i

K_m

V_{max}

Miscellaneous

degrees of temperature

°C

gravity

g

median doses

LD₅₀, ED₅₀, etc.

optically isometric forms

d-, l-, dl-

routes of drug administration

i.v., i.p., s.c., i.m.

standard deviation

S.D.

standard error

S.E.

Units of electricity

volt	V
ampere	A
cycles/sec	Hz

Units of radioactivity

curie	Ci
counts per min	cpm
disintegrations per min	dpm
roentgen	r

Units of time

hour	hr or h
minute	min or m
second	sec or s

Whenever an abbreviation other than those above is to be used in a manuscript, it is to be defined in the text or in a footnote thereto, the first time it is used. Abbreviations for commonly used substances should be those recommended by the Journal of Biological Chemistry. Abbreviations for drugs may be used if properly defined on first use and if the chemical or generic name of the drug is given when the abbreviation is first used. Abbreviations may be used in the running title but not in the full title of the manuscript.

Drugs

Generic names should be used in text, tables and figures. Trade names may be mentioned in parentheses in the first text reference to the drug but should not appear in titles, figures or tables. When a trade name is used, it should be capitalized; generic or chemical names are not capitalized. The chemical nature of new drugs must be given when it is known. The form of drug used in calculations of doses (e.g., base or salt) should be indicated. When several drugs are used, it may save space to include a separate paragraph in "Methods," or a separate table or footnote, listing the relevant information about all drugs employed.

Page Charges

Authors are assessed page charges at the rate of \$30 per printed page. With the page proof, authors will receive a request for information concerning such charges. These charges will be assessed only if they involve no personal expense to the authors. Request for waiver should be addressed to the ASPET Executive Officer at the time billing is received.

The cost of a limited number of illustrations will be borne by the Journal; the cost of excessive illustrations and of colored illustrations will have to be defrayed by the authors.

After acceptance: When the field editor recommends acceptance of an article for publication, authors are encouraged to submit electronic diskettes of the final version along with the typed REVISED manuscript. The author will receive a packet of information containing copyright forms and detailed instructions pertaining to the publication of their manuscript.

Reprints and page charges. An order form for reprints as well as information on the estimation of page charges will be mailed with the galley proof. Please direct questions on page charges, or other business matters to Kay Croker, Executive Officer, American Society for Pharmacology and Experimental Therapeutics, 9650 Rockville Pike, Bethesda, MD 20814.